(Q43962182)

28 November 2017

title

Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses (English)

1 reference

pneumococcal conjugate vaccine

28 November 2017

main subject

1 reference

9

Elisabeth A M Sanders

1 reference

28 November 2017

7

Loek van Alphen

1 reference

28 November 2017

Gerwin D Rodenburg

1

1 reference

28 November 2017

Elske J M van Gils

2

1 reference

28 November 2017

Reinier H Veenhoven

3

1 reference

28 November 2017

Nienke Jones

4

1 reference

28 November 2017

Irina Tcherniaeva

5

1 reference

28 November 2017

Eelko Hak

6

1 reference

28 November 2017

Guy A M Berbers

8

1 reference

28 November 2017

language of work or name

English

0 references

publication date

18 November 2009

1 reference

28 November 2017

1 reference

28 November 2017

volume

28

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

1391-1396

1 reference

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Antibody Responses to Nasopharyngeal Carriage ofStreptococcus pneumoniaein Adults: A Longitudinal Household Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

The impact of pneumococcal conjugate vaccines on otitis media-can we extrapolate to pneumonia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Universal childhood immunisation against Streptococcus pneumoniae: The five-year experience of Liguria Region, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Anticapsular Serum Antibody Concentration and Protection against Pneumococcal Colonization among Children Vaccinated with 7-Valent Pneumococcal Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.151

10.1016/J.VACCINE.2009.10.151

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference